Search

Search Constraints

You searched for: Author/Creator Platzbecker, U.

Search Results

42. P509: CLONAL HEMATOPOIESIS-ASSOCIATED MUTATIONS AS MEASURABLE RESIDUAL DISEASE MARKERS IN ACUTE MYELOID LEUKEMIA PATIENTS FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION. (23rd June 2022)

43. P529: FIRST EUROPEAN REAL-WORLD EVIDENCE PROSPECTIVE REGISTRY OF FIRST-LINE ADULT PATIENTS WITH BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM TREATED WITH FIRST-IN-CLASS CD123-TARGETED THERAPY TAGRAXOFUSP. (23rd June 2022)

44. P545: CHARACTERISTICS AND OUTCOME OF PATIENTS WITH ACUTE MYELOID LEUKEMIA AND TRISOMY 19. (23rd June 2022)

45. P561: VIALE-T: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF VENETOCLAX IN COMBINATION WITH AZACITIDINE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA. (23rd June 2022)

46. P573: PHARMACOKINETIC EXPOSURE EQUIVALENCE AND PRELIMINARY EFFICACY AND SAFETY FROM A RANDOMIZED CROSS OVER PHASE 3 STUDY OF AN ORAL HYPOMETHYLATING AGENT DEC-C COMPARED TO IV DECITABINE IN AML PATIENTS. (23rd June 2022)

48. P747: LR-MDS IS CHARACTERIZED BY DIFFERENTIAL EXPRESSION OF INFLAMMASOME-RELATED GENES IN SPECIFIC CELL POPULATIONS. (23rd June 2022)

49. P752: TARGETING S100A9 IN THE MYELODYSPLASTIC INFLAMMATORY BONE MARROW MICROENVIRONMENT BY TASQUINIMOD IMPROVES THE SUPPORTIVE FUNCTION OF MESENCHYMAL STROMAL CELLS. (23rd June 2022)

50. P778: LONG-TERM UTILIZATION AND BENEFIT OF LUSPATERCEPT IN PATIENTS (PTS) WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) FROM THE MEDALIST TRIAL. (23rd June 2022)